CONSHOHOCKEN, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 2:30 P.M. ET. The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events page. A replay of the webcast will be available after the event. About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharm ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

Key Takeaways MDGL posted a Q4 loss of $2.57 per share as operating expenses surged sharply.Rezdiffra sales drove $321.1M in Q4 revenues, beating estimates on strong demand.Madrigal ended 2025 with $958.4M in sales as phase III studies advance toward full approval.Madrigal Pharmaceuticals (MDGL) reported a fourth-quarter 2025 loss of $2.57 per share, in contrast to the Zacks Consensus Estimate of earnings of 4 cents. The large difference is mainly due to a significant rise in operating expenses. In the same ...

Company Updates - Madrigal Pharmaceuticals experienced a significant drop in shares despite reporting fourth-quarter sales of $321 million for its liver disease drug Rezdiffra, exceeding consensus estimates by $10 million, with all metrics being positive [2] - Daiichi Sankyo appointed former Novartis executive John Tsai as the new global head of research and development, effective April 1, replacing Ken Takeshita [3] - Johnson & Johnson announced an investment of over $1 billion in a new cell therapy manufacturing facility in Pennsylvania, part of a broader $55 billion commitment to U.S. production by early 2029 [4] - Johnson & Johnson has temporarily paused enrollment in a mid-stage trial for an Alzheimer's vaccine co-developed with AC Immune, with the halt not related to new safety findings [5] - Novartis is collaborating with biotech startup Unnatural Products to develop a macrocyclic peptide drug, providing $100 million upfront and potentially $1.7 billion if the drug progresses [6] Industry Insights - The pharmaceutical industry is seeing significant investments in manufacturing and research, with companies like Johnson & Johnson committing substantial funds to U.S. production and new drug development initiatives [4][6] - The trend of appointing experienced executives from major pharmaceutical companies to lead research and development efforts indicates a focus on enhancing innovation and drug development capabilities within the industry [3]

Management said patient growth continued through the fourth quarter. The company reported ending the quarter with more than 36,250 patients on Rezdiffra, up from more than 29,500 at the end of the third quarter. Sibold noted the patient figure reflects the net of new starts and discontinuations.Sibold attributed the commercial performance to building the market “from scratch,” including prescriber education, establishing care pathways, expanding prescriber breadth and depth, and contracting for access. He a ...

Stock of Madrigal Pharmaceuticals, Inc. (MDGL) is falling about 11 percent on Thursday morning trading despite reporting positive fourth quarter financial results, which saw a drop in net loss to $58.58 million, or $2.57 per share, from $59.42 million, or $2.71 per share, last year.The company's stock is currently trading at $436.13, down 11.33 percent or $55.71, over the previous close of $491.49 on the Nasdaq. It has traded between $265.00 and $615.00 in the past one year.The company's revenue for the qu ...

Madrigal (MDGL) came out with a quarterly loss of $2.57 per share versus the Zacks Consensus Estimate of $0.04. This compares to a loss of $2.71 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -7,442.86%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.98 per share when it actually produced a loss of $5.08, delivering a surprise of -156.57%.Over the last four quarters, the company has ...

Financial Performance - The company has an accumulated deficit of $2,090.5 million as of December 31, 2025, and has incurred losses since inception [422]. - Product revenue for the year ended December 31, 2025, was $958.4 million, a 432% increase from $180.1 million in 2024, driven by increased demand for Rezdiffra and a full year of commercialization [448]. - Cost of sales for 2025 was $56.1 million, up 801% from $6.2 million in 2024, reflecting the same factors as product revenue [449]. - Research and development expenses increased to $388.5 million in 2025, a 64% rise from $236.7 million in 2024, primarily due to business development transactions [450]. - Selling, general and administrative expenses rose to $813.8 million in 2025, an 87% increase from $435.1 million in 2024, mainly due to increased commercial activities for Rezdiffra [451]. - Interest income decreased to $37.4 million in 2025 from $46.7 million in 2024, primarily due to higher principal balances and interest rates [452]. - Interest expense increased to $22.3 million in 2025, up 52% from $14.7 million in 2024, due to a higher average outstanding principal balance [453]. - For the year ended December 31, 2025, net cash used in operating activities was $189.6 million, primarily due to losses from operations [475]. - The company reported net cash provided by financing activities of $735.1 million for the year ended December 31, 2024, mainly from the 2024 Offering [480]. Product Development and Commercialization - Rezdiffra, the company's medication for MASH, was approved by the FDA in March 2024 and began generating revenue in April 2024 [419]. - The company launched Rezdiffra in Germany in September 2025, marking it as the first medication approved for noncirrhotic MASH with moderate to advanced liver fibrosis [419]. - The company plans to evaluate additional therapies to expand the eligible patient population for Rezdiffra [423]. - The company expects fluctuations in financial results based on net sales of Rezdiffra and the progress of research and development efforts [423]. - The company has acquired rights to several new drug candidates, including MGL-2086 and ervogastat, to enhance its pipeline for MASH treatment [420]. - The company received FDA approval for Rezdiffra in March 2024 and EC approval in August 2025, with a tiered royalty payable to Roche on net sales [484]. - In July 2025, the company entered into a license agreement with CSPC for MGL-2086, paying an upfront fee of $120.0 million and potential milestone payments of up to $2.0 billion [485]. Operational Expenses and Future Outlook - The company expects to incur additional operating losses due to planned expenditures for commercializing Rezdiffra and expanding operations in Europe [422]. - Research and development expenses are expected to remain substantial as the company conducts clinical trials and manufacturing studies [429]. - Selling, general and administrative expenses are anticipated to increase as the company expands its operations and commercialization efforts [433]. - The company anticipates continued losses until sufficient revenue is generated from Rezdiffra and other future products, with potential future capital needs for operations [457]. Financing and Cash Position - As of December 31, 2025, cash, cash equivalents, restricted cash, and marketable securities totaled $988.6 million, compared to $931.3 million in 2024 [455]. - The company entered into a Financing Agreement on July 17, 2025, providing up to $500.0 million in senior secured credit facilities [462]. - As of December 31, 2025, the outstanding principal under the Financing Agreement was $350.0 million, with an interest rate of 8.75% [467]. - The company has approximately $268.3 million in obligations related to agreements for active pharmaceutical ingredients as of December 31, 2025 [488]. - The company has not entered into any hedging arrangements for foreign currency risk as it expands operations into Europe [492]. - Inflation has not materially affected the company's financial condition or results of operations during the years ended December 31, 2025, 2024, or 2023 [494]. Public Offerings - In March 2024, the company completed a public offering, selling 750,000 shares at $260.00 per share and pre-funded warrants for 1,557,692 shares at $259.9999 each, raising approximately $659.9 million in net proceeds [468][469]. - The 2023 public offering closed on October 3, 2023, with gross proceeds of $500.0 million and net proceeds of approximately $472.0 million after expenses [471][472].

Madrigal Pharmaceuticals (NasdaqGS:MDGL) Q4 2025 Earnings call February 19, 2026 08:00 AM ET Company ParticipantsBill Sibold - CEODavid Soergel - CMOMardi Dier - CFOTina Ventura - Chief Investor Relations OfficerYasmeen Rahimi - 5-star analyst and MdConference Call ParticipantsAlex Thompson - AnalystEllie Merle - Senior Biotech Equity Research AnalystJay Olson - Md and Senior Biotechnology AnalystJonathan Wolleben - Md and Senior Research AnalystManoj Garg - AnalystMichael DiFiore - Equity Research AnalystP ...

Madrigal Pharmaceuticals (NasdaqGS:MDGL) Q4 2025 Earnings call February 19, 2026 08:00 AM ET Company ParticipantsBill Sibold - CEODavid Soergel - CMOMardi Dier - CFOTina Ventura - Chief Investor Relations OfficerYasmeen Rahimi - 5-star analyst and MdConference Call ParticipantsAlex Thompson - AnalystEllie Merle - Senior Biotech Equity Research AnalystJay Olson - Md and Senior Biotechnology AnalystJonathan Wolleben - Md and Senior Research AnalystManoj Garg - AnalystMichael DiFiore - Equity Research AnalystP ...